The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.
Scientific presentation selector
Geo Regions
Important Notice Regarding the Scientific Information You Have Requested
You are being redirected to the scientific presentations section. The information provided here relate to investigational assets. The safety and efficacy of the unapproved assets has not been proven.
Please acknowledge that you understand this before proceeding.
BackImportant Notice: The information provided here relates to investigational therapies. The safety and efficacy of these investigational therapies has not been proven.
Poster
Open-label phase 1 study to evaluate the safety of SGN-35T in patients with relapsed/refractory CD30-expressing lymphoid malignancies (SGN35T-001; trial in progress)
Feldman T, Ramchandren R, Lee HJ, Popradi G, Collins GP, Morillo D, Yan M, Chen TL, Kim YH
CD30-directed Antibody-Tripeptide MMAE Conjugate | October 26, 2024 | ISHL 2024
C5811001 | NCT06120504
